Global Intragastric Balloons Market 2015-2019
About Intragastric Balloon
Obesity is a medical condition associated with the accumulation of excess fat. A person with a body mass index of 30 or more is considered obese. According to the WHO, more than 1.9 billion adults aged 18 years and above were overweight in 2014. Worldwide there are more than 671 million obese people, particularly in countries such as the US, Brazil, Belgium, Mexico, Germany, France, Egypt, Russia, the UK, and Australia. In European countries, 26% of the male and 24% of the female population are estimated to be obese. Obesity is linked to many life-threatening conditions and results in the deaths of 2.8 million people each year. Bariatric surgery is one of the most common treatment methods for obesity. This procedure helps reduce weight by restricting the amount of food that the stomach can hold. Intragastric balloon surgery involves the insertion of a silicone balloon into the stomach as a temporary weight loss measure.
Technavio's analysts forecast the global intragastric balloon market to grow at a CAGR of 6.93% during 2014-2019.
Covered in this Report
Technavio's report, Global Intragastric Balloon Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report includes a discussion of the key vendors operating in this market.
Technavio Announces the Publication of its Research Report – Global Intragastric Balloons Market 2015-2019
Technavio recognizes the following companies as the key players in the Global Intragastric Balloons Market: Apollo Endosurgery, Helioscopie Medical Implants and Spatz FGIA
Other Prominent Vendors in the market are: Allurion, BaroNova Therapeutics, Districlass Medical, Endalis, Fengh Medical, Lexal Srl, Life Partners Europe, Medicone, Medsil, Obalon Therapeutics, Phagia Technologies, PlenSat, ReShape Medical, Shandong Institute of Medical Instruments, Silimed, Sterlab and Tulip Medical Products
Commenting on the report, an analyst from Technavio’s team said: “The demand for better healthcare services and improved patient outcomes without a significant rise in healthcare costs has been increasing. Healthcare providers are also focusing on patient safety. To reshape healthcare delivery and to change the structure of the healthcare industry there are two dominant trends: growth and consolidation. Vendors are trying to address the issues associated with intragastric balloons such as dislocation and infection by conducting more clinical research. Therefore, changes in the healthcare industry are expected to drive the market.”
According to the report, more than 50% of people, i.e., 671 million, are obese, worldwide. In the US, two-thirds of the population is overweight. In Europe, 26% of the male and 24% of the female population are estimated to be obese. In addition, many countries in Asia such as Malaysia, Singapore, and South Korea are reporting high incidences of obesity, and, consequently, higher rates of diabetes, hypertension, and weight-related disabilities. Food habits and sedentary lifestyles are the major obesity-causing factors. Therefore, the rise in the incidence and prevalence of obesity are driving the growth of the market.
Further, the report states that complications related to the intragastric balloon are a major challenge in the market.
Apollo Endosurgery, Helioscopie Medical Implants, Spatz FGIA, Allurion, BaroNova Therapeutics, Districlass Medical, Endalis, Fengh Medical, Lexal Srl, Life Partners Europe, Medicone, Medsil, Obalon Therapeutics, Phagia Technologies, PlenSat, ReShape Medical, Shandong Institute of Medical Instruments, Silimed, Sterlab, Tulip Medical Products
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook